NCT00973700View on ClinicalTrials.gov

Safety and Immunogenicity of A/H1N1-SOIV (Swine Flu) Vaccine With and Without Adjuvant in Children, Adolescents and Adults (3 to 64 Years)

PHASE3CompletedINTERVENTIONAL
Enrollment

784

Participants

Timeline

Start Date

August 31, 2009

Primary Completion Date

October 31, 2009

Study Completion Date

October 31, 2010

Conditions
Novel 2009 Influenza H1N1
Interventions
BIOLOGICAL

MF59-eH1N1_f

MF59 adjuvanted (adj) egg-derived A/H1N1 with traces of Thiomersal

BIOLOGICAL

eH1N1_f

Unadjuvanted egg-derived A/H1N1 with traces of Thiomersal

Trial Locations (1)

Unknown

Instituto de Atencion Pediatrica, Avenida 0-2 Calle 22, Paseo Colon del Restaurante La, Bastilla 50 metros Sur, Edificio 5., San José

Sponsors

Lead Sponsor

Novartis Vaccines
All Listed Sponsors
lead

Novartis Vaccines

INDUSTRY

NCT00973700 - Safety and Immunogenicity of A/H1N1-SOIV (Swine Flu) Vaccine With and Without Adjuvant in Children, Adolescents and Adults (3 to 64 Years) | Biotech Hunter | Biotech Hunter